Comorbidity and Disability Dynamics in Multiple Sclerosis

Multiple sclerosis is a chronic autoimmune condition characterised by demyelination in the central nervous system and a heterogeneous clinical course. Beyond neurological injury, people with MS frequently experience additional health conditions—comorbidities—that include cardiovascular disease, metabolic syndrome, psychiatric disorders and other autoimmune diseases. Such comorbidities often precede or accompany the onset of MS symptoms and can accelerate disability progression, as measured by validated scales, and worsen outcomes for mobility, cognition and quality of life. Vascular risk factors such as hypertension and dyslipidaemia have been linked to higher relapse rates and increased lesion burden on imaging, while depression and anxiety correlate with greater fatigue and reduced adherence to disease-modifying therapies. Metabolic comorbidities, including obesity and insulin resistance, contribute to systemic inflammation, compounding neural injury and impairing rehabilitation efforts. Epidemiological studies reveal disparities in comorbidity prevalence across regions and among underrepresented groups, underscoring the need for tailored models of multidisciplinary care. Integrating routine screening and management of coexisting conditions into MS care pathways offers the potential to mitigate disability accrual and improve long-term outcomes globally.

Research from Nature Portfolio

Recent work using advanced echocardiographic techniques has demonstrated that individuals with MS exhibit subtle yet significant impairments in cardiac function compared to healthy controls. Quantitative analyses of left and right ventricular ejection fraction, longitudinal myocardial velocities and global longitudinal strain revealed reduced systolic and diastolic performance despite preserved arterial and endothelial parameters. These findings suggest that autonomic dysfunction and systemic inflammation in MS extend beyond the nervous system to impair cardiac mechanics. Early detection of such subclinical cardiovascular alterations may inform screening strategies and guide prompt interventions to prevent progression towards symptomatic heart failure in this population.

Comorbidity and Disability Dynamics in Multiple Sclerosis publication trend

The graph below shows the total number of articles in comorbidity and disability dynamics in multiple sclerosis across all publications each year (not limited to Nature Index journals).

Technical terms

Comorbidity: The presence of one or more additional conditions coexisting with a primary disease, in this case MS.

Expanded Disability Status Scale (EDSS): A method for quantifying neurological disability in MS, based on functional system scores and ambulation.

Speckle tracking echocardiography: A non-invasive imaging technique that tracks natural acoustic markers in the heart to assess myocardial deformation and function.

Global longitudinal strain: A measure of myocardial fibre shortening in the longitudinal axis, used to detect subtle changes in cardiac systolic function.

References

1. Etiology, effects and management of comorbidities in multiple sclerosis: recent advances. Frontiers in Immunology (2023).
2. A global view of comorbidity in multiple sclerosis: a systematic review with a focus on regional differences, methodology, and clinical implications. Journal of Neurology (2020).
3. Impaired Cardiac Function in Patients with Multiple Sclerosis by Comparison with Normal Subjects. Scientific Reports (2018).
4. Prevalence and epidemiology of stroke in patients with multiple sclerosis: a systematic review and meta-analysis. Journal of Neurology (2024).
5. Management of vascular risk in people with multiple sclerosis at the time of diagnosis in England: A population-based study. Multiple Sclerosis Journal (2023).
6. Impact of insulin resistance and metabolic syndrome on disability in patients with multiple sclerosis. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery (2020).